BrianMSlomovitzMD

Obstetrics & Gynecology • Fort Lauderdale, FL

Gynecologic Oncology

Division Chief Gynecologic Oncology

Join to view full profile

Dr. Slomovitz is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Slomovitz's full profile

Already have an account?

Office
1600 S Andrews Ave
Fort Lauderdale, FL 33316
Phone+1 954-355-4345

Fax+1 954-527-4889

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Gynecologic Oncology, 2002 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Obstetrics and Gynecology, 1998 - 2002
Rutgers New Jersey Medical SchoolClass of 1998

Certifications & Licensure

FL State Medical License 2014 - 2026
NJ State Medical License 2008 - 2015
TX State Medical License 2002 - 2015
NY State Medical License 1999 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology
American Board of Obstetrics and Gynecology Gynecologic Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACOG) American Congress of Obstetricians and Gynecologists

Clinical Trials

Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
Completed
Phase 3
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer Start of enrollment: 2009 Jun 29
Active, not recruiting
Phase 3
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 2
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus Start of enrollment: 2010 Jan 01
Terminated
Phase 2
Observation in Patients With Early-Stage Vulvar Cancer Undergoing Sentinel Lymph Node Dissection Start of enrollment: 2012 Jan 03
Active, not recruiting
Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer Start of enrollment: 2015 May 21
Active, not recruiting
Phase 2
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer Start of enrollment: 2018 Sep 06
Terminated
Phase 2
Ribociclib and Letrozole Treatment in Ovarian Cancer Start of enrollment: 2018 Dec 14
Active, not recruiting
Phase 2
Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer Start of enrollment: 2021 Feb 22
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled...
Annika Auranen, Matthew A Powell, Vladyslav Sukhin, Lisa M Landrum, Graziana Ronzino
Therapeutic Advances in Medical Oncology. 2024-01-01
61 citations
Radiotherapy Versus Inguinofemoral Lymphadenectomy as Treatment for Vulvar Cancer Patients With Micrometastases in the Sentinel Node: Results of GROINSS-V II
Maaike H. M. Oonk, Brian Slomovitz, Peter Baldwin, Helena C. van Doorn, Jacobus van der Velden
Journal of Clinical Oncology. 2021-08-25
30 citations
Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial.
Jung-Min Lee, Richard G Moore, Sharad Ghamande, Min S Park, John P Diaz
Clinical Cancer Research. 2022-10-03

Lectures

Low-Grade Serous Ovarian Cancer: State of the Science
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

New Cervical Cancer Treatment Approach Could Reduce Risk of Death by 40%, Trial Results ShowOctober 22nd, 2024
Pembrolizumab Aids Survival with High-Risk Endometrial CancerOctober 22nd, 2024
Study Investigates Combination Treatment for Endometrial CancerMarch 28th, 2023
Join now to see all